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Botulinum neurotoxins translocate their enzymatic domain across vesicular membranes. The
molecular triggers of this process are unknown. Here, we tested the possibility that this is elicited
by protonation of conserved surface carboxylates. Glutamate-48, glutamate-653 and aspartate-877
were identiﬁed as possible candidates and changed into amide. This triple mutant showed increased
neurotoxicity due to faster cytosolic delivery of the enzymatic domain; membrane translocation
could take place at less acidic pH. Thus, neutralisation of speciﬁc negative surface charges facilitates
membrane contact permitting a faster initiation of the toxin membrane insertion.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction metalloprotease activity and hydrolyse particular SNAREs (solubleBotulinum neurotoxins (BoNTs, serotypes A–G) are extremely
potent toxins, produced by bacteria of the genus Clostridium, that
are classiﬁed as Category A bioterrorism agents by the Centers
for Disease Control [1,2], but are effective therapeutics for the
treatment of conditions caused by hyperactivity of cholinergic
nerve terminals [3,4].
The toxins are produced as 150 kDa single-chain proteins and
are subsequently proteolytically activated. The resulting heavy
chain (HC, 100 kDa) and light chain (LC, 50 kDa) remain
connected via a single disulﬁde bridge. The LCs exhibit zincN-ethyl maleimide sensitive factor attachment protein receptors),
among them synaptobrevin/(vesicle associated membrane protein)
VAMP-2 and SNAP-25 (synaptosomal-associated protein of
25 kDa) inside target neurons [5–8]. SNARE cleavage blocks release
of neurotransmitters causing a ﬂaccid paralysis that can lead to
respiratory failure and death [9].
The HC of BoNTs consists of three domains, two of which, HCN
and HCC, 25 kDa each, form the carboxyl-terminal half of HC, re-
ferred to as the HC-fragment. HC mediates binding of the toxins to
their cellular receptors: polysialogangliosides and synaptic vesicle
proteins [10–12]. The synaptic vesicle protein SV2 mediates the
entry of BoNT/A and E [13–15], whereas synaptotagmin is
exploited by BoNT/B and G and the mosaic type BoNT/DC [16–
19]. The binding sites for gangliosides and the protein receptor
are located within HCC. The function of HCN is less clear. HCNA
exhibits low afﬁnity for phosphatidylinositolmonophosphate [20]
and HCNE has recently been reported to contribute to SV2 binding
[21]. After the toxin has been taken up by receptor mediated endo-
cytosis at nerve terminals the N-terminal half (HN, designated
translocation domain) of HC, forms upon acidiﬁcation a protein-
conducting channel in the membrane of vesicles through which
the LC is delivered to the cytosol [6,22]. Membrane interaction
and channel formation are the least characterised steps of the poi-
soning process.
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served carboxylates triggers the interaction of the toxin with the
negatively charged membrane surface [23]. We chose to begin
our study with BoNT/B because of the higher resolution of its crys-
tallographic structure [24]. We show that neutralisation of three
speciﬁc carboxylates leads to increased LC translocation at less
acidic pH and that these mutations increase the biological activity
of BoNT/B at the neuromuscular junction, which is its natural site
of action. Taken together these data suggest that protonation of
speciﬁc carboxylates constitutes a trigger required for membrane
translocation of BoNT/B LC.
2. Materials and methods
2.1. Toxins
Mutants of BoNT/B (derived from strain Okra) were generated
employing the GeneTailor™ site-directed mutagenesis system
(Invitrogen) using suitable primers and pBoNTBS [25] as template
DNA. Nucleotide sequences of all mutants were veriﬁed by DNA
sequencing.
BoNT/B and its mutants were produced in Escherichia coli and
puriﬁed as previously described [25]. For studies in cultured cells,
single-chain BoNT/B preparations were activated with immobilised
trypsin (Sigma–Aldrich; 0.002 U/lg BoNT) for 30 min at 21 C
yielding > 95% of di-chain toxin. Toxin concentrations and the de-
gree of activations were determined by densitometry subsequent
to SDS–PAGE and Coomassie blue staining using a LAS-3000 imag-
ing system (Fuji Photo Film, Co., Ltd.), the AIDA 3.51 program, and
BSA as protein standard.
2.2. Mouse phrenic nerve toxicity assay
The mice phrenic nerve (MPN) toxicity assay was set up as pre-
viously described [25]. The time required to decrease the ampli-
tude to 50% of the starting value (paralytic halftime) was
measured. Single-chain BoNT/B was applied in quadruplicates at ﬁ-
nal concentrations of 0.1, 0.3, and 1 nM to plot a dose–response
curve to which the power function y = 58.526x0.2255 could be as-
cribed. BoNT/B mutants were tested at least in triplicates at
1 nM, BoNT/B-E48Q/E653Q/D877N (BoNT/B-TM) at 0.1, 0.3, and
0.7 nM, ﬁnal concentrations. The resulting paralytic halftimes were
converted to the corresponding concentrations of wild-type BoNT/
B (BoNT/B-WT) using the equation mentioned above. The toxicities
were ﬁnally expressed as percentage of the wild-type activity.
2.3. Kinetics of BoNT/B translocation in primary neurons
Primary cultures of rat cerebellar granule neurons (CGNs) were
prepared from 6- to 8-days-old rats as previously described [26].
Cultures were maintained in Eagle’s basal medium supplemented
with 10% FBS, 25 mM KCl, 2 mM glutamine and 50 lg/ml gentami-
cin at 37 C, 5% CO2, 95% humidity. CGNs were used at 6–7 days
in vitro.
CGNs were treated with 1 nM wild-type or mutant BoNT/B in
culture medium, and, at indicated time points, Baﬁlomycin A1
(BafA1; Sigma) was added to a ﬁnal concentration of 100 nM and
the incubation prolonged for additional 12 h; cells were lysed
and amount of VAMP-2 was estimated by immunoblot analysis.
2.4. Assay of SNARE cleavage in rat PC12-SYT N24Q by BoNT/B after
transient low pH exposure
PC12 cells stably expressing the chimeric synaptotagmin-I(1–
140)/EGFP protein at the plasma membrane (PC12-SYT N24Q;[23]) were plated onto 100 mm Petri dishes and maintained in Ros-
well Park Memorial Institute medium supplemented with 10%
horse serum, 5% FBS, 2 mM GlutaMAX (Life Technologies), 100 U/
ml penicillin, 100 lg/ml streptomycin, 250 ng/ml amphotericin B,
and 50 lg/ml of Geneticin at 37 C in a humid incubator.
A total of 5  104 PC12-SYT N24Q cells were seeded into 24-
well plates; after cell adhesion, 50 lg of puriﬁed GT1b gangliosides
(Santa Cruz) were added, and after 24 h cells were washed twice
with ice-cold PBS (phosphate buffered saline). They were then
incubated with toxin in minimum essential medium (MEM), 10%
FBS, pH 7.4, and left at 4 C for 15 min. After washing twice with
the same cold medium, pre-warmed medium A (123 mM NaCl,
6 mM KCl, 0.8 mM MgCl2, 1.5 mM CaCl2, 5 mM NaPi, 5 mM citric
acid, 5.6 mM glucose, 10 mM NH4Cl), adjusted to different pH val-
ues with 1 M Tris-base, was added and left for indicated times.
Cells were then washed twice with MEM and further incubated
in MEM, 10% FBS, pH 7.4, containing 100 nM BafA1 for 12 h.
BoNT/B translocation was evaluated following their speciﬁc prote-
olytic activity by immunoblot analysis of VAMP-2.
2.5. Immunoblotting
Cells were lysed with 100 mM Tris–HCl, 1% SDS, pH 6.8, con-
taining protease inhibitors (complete Mini EDTA-free; Roche). Pro-
tein concentration was determined with the BCA test (Pierce BCA
protein assay, Thermo Scientiﬁc), and equal amounts were loaded
onto a 4–12% NuPage gel (Invitrogen) and separated in MES buffer
(Invitrogen). Proteins were then transferred onto Protran nitrocel-
lulose membranes (Whatman) and then saturated for 1 h in PBS-T
(PBS, 0.1% Tween 20) containing 5% non-fat milk. Incubation with
primary antibodies speciﬁc for VAMP-2 (monoclonal 69.1, Synaptic
System, Germany), or SNAP-25 (polyclonal, produced by injecting
in rabbit the C-terminal peptide ANQRATKMLGSG of SNAP-25 con-
jugated to keyhole limpet hemocyanin [23]), was performed over-
night at 4 C. The membranes were washed three times with PBS-T
and incubated with secondary horseradish peroxidase-conjugated
antibodies. Finally, membranes were washed several times with
PBS-T and visualisation was carried out using Luminata Crescendo
(Merck Millipore). The degree of VAMP-2 cleavage was determined
as the ratio versus SNAP-25.
3. Results
The molecular mechanism that facilitates integration of the
translocation domain of BoNTs into lipid bilayers upon drop of
pH is unknown. There are no histidine residues in HN, but, among
conserved negatively charged residues of the presently known iso-
forms of BoNTs [23], we have identiﬁed Glu-48, Glu-653, and Asp-
877 of BoNT/B (Fig. S1) as amino acids whose charged side chains
should be protonatable at physiological vesicular pH using an ad
hoc software program [27]. Accordingly, we replaced the carboxyl-
ates with amides generating single, double and triple BoNT/B mu-
tants and studied whether the mutations affect the biological
activity at its natural site of action, cholinergic nerve terminals in
MPN hemidiaphragm assays. Table 1 shows that BoNT/B-TM
shortened the time to 50% paralysis compared to BoNT/B-WT from
99 to 88 min at 0.1 nM toxin concentration. This corresponds to a
1.6-fold increase in neurotoxicity. This ﬁnding was further vali-
dated by recording a dose–response curve for BoNT/B-TM which
provides the result predicted by pharmakokinetics, i.e. that the
difference among BoNT/B-TM and BoNT/B-WT increases as their
concentration is decreased (Fig. S2). In contrast to BoNT/B-TM,
BoNT/B-E48Q exhibited even signiﬁcantly diminished neurotox-
icity. However, double mutants comprising Asn-877 showed
increased neurotoxicity compared to BoNT/B-E48Q/E653Q and
Table 1
Toxicity of various BoNT/B mutants at mice phrenic nerve hemidiaphragm
preparations.
BoNT/B Concentration
(nM)
50% paralysisa
(min)
Normalised
toxicityb (%)
Wild-type 1 59 ± 4 100 ± 7
(WT) 0.3 75 ± 5 112 ± 7
0.1 99 ± 5 100 ± 5
E48Q/E653Q/D877 N 0.3 70 ± 6 154 ± 14
(TM) 0.1 88 ± 2 168 ± 4
E653Q/D877 N 1 55 ± 2 132 ± 4
E653 K/D877 N 1 55 ± 4 128 ± 8
E48Q/E653Q 1 69 ± 5 62 ± 4
E48Q/E653 K 1 61 ± 6 91 ± 8
E48Q/D877 N 1 58 ± 5 108 ± 9
E48Q 1 81 ± 14 36 ± 6
E653Q 1 66 ± 2 69 ± 3
E653 K 1 62 ± 2 85 ± 2
D877 N 1 63 ± 9 80 ± 11
a Data are means ± S.D. (n = 3–5).
b To a three point dose–response-curve of wild-type scBoNT/B a power function
was ﬁtted (y = 58.526x0.2255). For each mutant the correlative concentration was
calculated and expressed as percent toxicity of wild-type scBoNT/B.
Fig. 1. Time course of BafA1 mediated inhibition of LC delivery of BoNT/B wild-type
and triple mutant in rat CGNs. Cells were incubated in the presence of 1 nM BoNT/B
wild-type (WT) or triple mutant (TM) in culture medium containing 25 mM KCl.
BafA1 was added at indicated times. After 12 h of incubation cells were lysed. (A)
Immunoblot analysis of VAMP-2 and SNAP-25 of a representative experiment using
speciﬁc antibodies. (B) Quantiﬁcation of VAMP-2 and SNAP-25 by densitometric
analysis. SNAP-25 was taken as the internal standard. Their ratios were plotted,
setting the value of non-treated cells (NC) to 1. Filled bars refer to BoNT/B-WT, open
bars to BoNT/B-TM. Values are means ± S.D. of three experiments performed in
duplicates.
Fig. 2. LC translocation of BoNT/B triple mutant requires less acidic extracellular
pH. PC12-SYT N24Q cells were incubated with 5 nM BoNT/B-WT (ﬁlled bars) or
BoNT/B-TM (open bars) at 4 C for 15 min, washed and incubated at 37 C with
buffers of the indicated pH value (abscissa) for 10 min, washed again at neutral pH
and incubated for 12 h with cell culture medium in the presence of BafA1 (100 nM).
Immunoblot analyses (A) and quantiﬁcation (B) were done as detailed in the legend
to Fig. 1. Values are means ± S.D. derived from three experiments performed in
duplicates. NC, non-treated control.
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ceeded to determine the time dependence of LC entry of the
BoNT/B-TM and of BoNT/B-WT into CGNs, which are a primary cul-
ture consisting of >95% neurons. Cleavage of the BoNT/B substrate
VAMP-2 was used as readout of LC/B entry. Preliminary in vitro
cleavage assays showed that the mutations did not interfere with
the proteolytic activity of BoNT/B LC (data not shown). Addition
of BafA1, which prevents acidiﬁcation of vesicles, at different time
intervals after toxin incubation shows that the majority of BoNT/B-
TM has completed membrane translocation within 60 min of incu-
bation, whereas translocation of BoNT/B-WT has not been com-
pleted even after 120 min (Fig. 1).
To study the pH dependence of membrane translocation, we
made use of a recently applied protocol that bypasses endocytosis
and induces the LC to enter the cytosol through the plasma mem-
brane in response to extracellular low pH exposure [23,28]. BoNT/
B-WT or BoNT/B-TM was administered in the cold at pH 7.4 to
PC12 cells that stably express the N-terminal domain of the
BoNT/B protein receptor synaptotagmin-I on their surface to allow
BoNT binding. This cell line guarantees enhanced BoNT/B binding
and consequently exhibits increased sensitivity of the cell system.
Cells were exposed for 10 min at 37 C to extracellular media of
various pH values, washed, and incubation continued at pH 7.4
in the presence of 100 nM BafA1. Fig. 2 shows that BoNT/B-TM,
in contrast to BoNT/B-WT, delivers decent amounts of LC to the
cytosol already at pH 6.0. More efﬁcient LC delivery of BoNT/B-
TM is also detectable at pH 5.5, and at pH 5.0 LC translocation of
BoNT/B-WT approximately reaches the level of BoNT/B-TM.
To inspect whether the translocation process follows similar
kinetics the extent of LC delivery at acidic pH was analysed at dif-
ferent time intervals (Fig. 3A). At pH 4.5 the initial rate of LC trans-
location of BoNT/B-TM translocation is increased compared to
BoNT/B-WT. The kinetics of BoNT/B-TM LC translocation slows
down at pH 5.5 compared to pH 4.5. At this pH condition, little
LC of BoNT/B-WT is translocated at all (Fig. 3B). Reduction of the
temperature to 28 C during low pH exposure drastically reduced
LC translocation of BoNT/B-WT and -TM. At pH 4.5 and pH 5.5
the amount of VAMP-2 versus SNAP-25 was at the most reduced
by 16% for BoNT/B-WT and BoNT/B-TM (Fig. 3C and D), indicating
that low temperature is not permissive for BoNT/B unlike for BoNT/
D and TeNT at CGNs [29]. In this regard BoNT/B behaves like BoNT/
C whose LC chain does not translocate in CGNs at 28 C [29].
Fig. 3. LC of BoNT/B triple mutant translocates faster than that of wild-type. PC12-SYT N24Q cells were incubated with BoNT/B-WT (ﬁlled bars) or BoNT/B-TM (open bars) and
treated as described, except that cells were exposed to external media of pH values of 4.5 or 5.5 (pH 7.4 served as control) and temperatures of 28 C or 37 C for varying time
intervals as indicated. Immunoblot analyses and quantiﬁcation were done as detailed in the legend to Fig. 1. Values are means ± S.D. values of three experiments performed in
duplicates. NC, non-treated controls.
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In the present study we investigated the question how the pro-
cess of membrane translocation of BoNTs is initiated. This mecha-
nism has to ensure that the toxins form a membrane channel only
after having reached the target cell membrane. This is signalled by
an acid pH environment inside synaptic vesicles. Therefore BoNT
amino acid sequences have been inspected for conserved residues
being protonatable around the intravesicular pH range [23]. Histi-
dine residues are responsible for sensing pH and inducing struc-
tural rearrangements of diphtheria toxin [30,31]. However, there
is no conserved histidine in BoNTs except for those implicated in
Zn2+ coordination in the LC, while there are several strictly con-
served Glu/Asp residues whose pKa values were estimated for
BoNT/B to be protonatable in the 4–7 range of pH values (Fig. 7
and Supplementary Table 1 of Ref. [23]). Of these, three are located
in the LC, six in the HN, and one in HCN in direct neighbourhood to
HN. Interestingly, they are all exposed on the same face of the toxin
[23]. It has been proposed that BoNT/B takes an upright position
when bound to its ganglioside and protein receptors due to its
mostly negatively charged surfaces at neutral pH [32]. Based on
this hypothesis, it is feasible that in acidic pH environment the face
exposing those carboxylates approaches the negatively charged
vesicular membrane surface upon protonation of particular car-
boxylates as a preliminary step towards insertion of the HN-do-
main. To study this possibility, E48 of the LC and E653 of HN
were selected because of their conservation and predicted slightly
acidic pKa values of their carboxylates (6.5 and 6.9, respectively)and replaced with glutamine. D877 of HCN has a high pKa and
was mutated to asparagine due to its close vicinity to a hydropho-
bic segment of HN amino acids [33,34] which was estimated to ex-
hibit a high membrane interaction propensity. If the mutated
residues would be key to initiation of membrane translocation,
then BoNT/B-TM should be more efﬁcient in LC delivery.
We found: (i) more rapid translocation of the LC of BoNT-TM in
cerebellar granule neurons; (ii) earlier onset of muscle paralysis at
MPN hemidiaphragm preparations; (iii) LC entry across the plasma
membrane of PC12 cells constitutively expressing synaptotagmin
on their surface at less acidic extracellular pH and (iv) increased
LC entry kinetics. These ﬁndings consistently support the view that
the selected residues have to become protonated in order to facil-
itate HN-mediated LC translocation. Protonation of additional
acidic residues is likely to be required for membrane integration
at later steps [35].
The assays performed do not provide direct information about
the particular step of the translocation process to which the indi-
vidual mutations assembled in BoNT/B-TM do contribute to. The
simplest explanation is that they facilitate approach of BoNT/B to
the negatively charged surface of the luminal layer of the synaptic
vesicle membrane. Since BoNT/B is attached to the target nerve cell
via its HCC domain, it is conceivable that membrane approach starts
form the C-terminus and Asp-877 of the toxin ﬁrst gets into con-
tact with the membrane. Accordingly, double mutants carrying
the D877Nmutation each showed increased toxicity (Table 1). Pro-
tonation of Asp-877 appears to be indispensible for subsequent
steps, as mutation of Glu-48 and Glu-653 alone did not show
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repelling charge of Glu-653 might also contribute to the increased
potency of BoNT/B-TM. However, Glu-653 might also act as a
switch to initiate local structural rearrangements. It is located on
the surface between the two long a-helices of HN (Fig. S1). Since
three hydrophobic phenylalanines, Phe-255, Phe-256 and Phe-
454, are positioned just opposite to its carboxylate, neutralisation
of its charge might expose a hydrophobic patch as a starting point
for LC separation from HN and other gross structural rearrange-
ment such as collapse of one large a-helix leading to membrane
integration of the above mentioned hydrophobic segment (aa
637–668). This may happen only in a membrane bound state, as
BoNT/B did not show major structural changes in acidic pH milieu
as isolated protein [33]. The protonation of Asp-877 might support
conformational changes in the hydrophobic segment 637–668
(Fig. S1). Protonation of E48 is less likely to simply facilitate the ap-
proach of the toxin’s surface to the membrane. E48 probably main-
tains a salt bridge with either R32 or K85 (Fig. S1). Lack of that salt
bridge might lead to partial unfolding of the LC which is believed to
be required for its transit through the HN channel [6,36,37] and
might in this way increase the toxin’s activity.
Though the speciﬁc effects caused by the three mutations re-
main to be determined, the present study, for the ﬁrst time, iden-
tiﬁes residues likely to act as molecular pH responsive switches in
the earliest phase of LC translocation. Detailed characterisation of
their mode of action shall provide further clues toward unveiling
the translocation mechanism of BoNTs. In any case, this paper pro-
vides proof of principle that the pharmacokinetics of a BoNT can be
changed by acting upon this part of the nanomachine involved in
its entry into the cytosol of neurons, in addition to what previously
known about changing binding and enzymatic properties.
Acknowledgements
The work carried out in the authors laboratories is supported in
part by grants from the Deutsche Forschungsgemeinschaft (BI 660/
3-1) to T.B., from the Bundesministerium für Bildung und Fors-
chung (FK031A212A) to A.R., and from MIUR (Progetto PRIN) and
of the University of Padova to O.R., from the Progetto Strategico
‘‘An in vivo Approach to the Physiopathology of Signal Transduc-
tion’’ of the University of Padova and from Fondazione CARIPARO
‘‘Synaptic Functions and Role of Glial Cells in Brain and Muscle Dis-
eases’’ to C.M.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.febslet.2013.
10.010.
References
[1] Arnon, S.S. et al. (2001) Botulinum toxin as a biological weapon: medical and
public health management. JAMA 285, 1059–1070.
[2] Centers for Disease Control and Prevention (CDC), D.o.H.a.H.S.H. (2012)
Possession, use, and transfer of select agents and toxins; biennial review.
Final Rule. Fed. Regist. 77, 61083–61115.
[3] Montecucco, C. and Molgo, J. (2005) Botulinal neurotoxins: revival of an old
killer. Curr. Opin. Pharmacol. 5, 274–279.
[4] Rosales, R.L., Bigalke, H. and Dressler, D. (2006) Pharmacology of botulinum
toxin: differences between type A preparations. Eur. J. Neurol. 13 (Suppl. 1), 2–
10.
[5] Blasi, J. et al. (1993) Botulinum neurotoxin A selectively cleaves the synaptic
protein SNAP-25. Nature 365, 160–163.
[6] Montal, M. (2010) Botulinum neurotoxin: a marvel of protein design. Annu.
Rev. Biochem. 79, 591–617.
[7] Schiavo, G., Benfenati, F., Poulain, B., Rossetto, O., Polverino de Laureto, P.,
DasGupta, B.R. and Montecucco, C. (1992) Tetanus and botulinum-Bneurotoxins block neurotransmitter release by proteolytic cleavage of
synaptobrevin. Nature 359, 832–835.
[8] Schiavo, G., Matteoli, M. and Montecucco, C. (2000) Neurotoxins affecting
neuroexocytosis. Physiol. Rev. 80, 717–766.
[9] Johnson, E.A. and Montecucco, C. (2008) Botulism. Handb. Clin. Neurol. 91,
333–368.
[10] Binz, T. and Rummel, A. (2009) Cell entry strategy of clostridial neurotoxins. J.
Neurochem. 109, 1584–1595.
[11] Rummel, A. (2013) Double receptor anchorage of botulinum neurotoxins
accounts for their exquisite neurospeciﬁcity. Curr. Top. Microbiol. Immunol.
364, 61–90.
[12] Simpson, L.L. and Rapport, M.M. (1971) The binding of botulinum toxin to
membrane lipids: sphingolipids, steroids and fatty acids. J. Neurochem. 18,
1751–1759.
[13] Dong, M., Liu, H., Tepp, W.H., Johnson, E.A., Janz, R. and Chapman, E.R. (2008)
Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E
into neurons. Mol. Biol. Cell 19, 5226–5237.
[14] Dong, M., Yeh, F., Tepp, W.H., Dean, C., Johnson, E.A., Janz, R. and Chapman, E.R.
(2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312,
592–596.
[15] Mahrhold, S., Rummel, A., Bigalke, H., Davletov, B. and Binz, T. (2006) The
synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A
into phrenic nerves. FEBS Lett. 580, 2011–2014.
[16] Dong, M., Tepp, W.H., Liu, H., Johnson, E.A. and Chapman, E.R. (2007)
Mechanism of botulinum neurotoxin B and G entry into hippocampal
neurons. J. Cell Biol. 179, 1511–1522.
[17] Nishiki, T., Kamata, Y., Nemoto, Y., Omori, A., Ito, T., Takahashi, M. and Kozaki,
S. (1994) Identiﬁcation of protein receptor for Clostridium botulinum type B
neurotoxin in rat brain synaptosomes. J. Biol. Chem. 269, 10498–
10503.
[18] Peng, L., Berntsson, R.P., Tepp, W.H., Pitkin, R.M., Johnson, E.A., Stenmark, P.
and Dong, M. (2012) Botulinum neurotoxin D–C uses synaptotagmin I and II as
receptors, and human synaptotagmin II is not an effective receptor for type B,
D–C and G toxins. J. Cell Sci. 125, 3233–3242.
[19] Rummel, A., Karnath, T., Henke, T., Bigalke, H. and Binz, T. (2004)
Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin
G. J. Biol. Chem. 279, 30865–30870.
[20] Muraro, L., Tosatto, S., Motterlini, L., Rossetto, O. and Montecucco, C. (2009)
The N-terminal half of the receptor domain of botulinum neurotoxin A binds
to microdomains of the plasma membrane. Biochem. Biophys. Res. Commun.
380, 76–80.
[21] Mahrhold, S., Strotmeier, J., Garcia-Rodriguez, C., Lou, J., Marks, J.D., Rummel,
A. and Binz, T. (2013) Identiﬁcation of the SV2 protein receptor-binding site of
botulinum neurotoxin type E. Biochem. J. 453, 37–47.
[22] Colasante, C., Rossetto, O., Morbiato, L., Pirazzini, M., Molgo, J. and
Montecucco, C. (2013) Botulinum neurotoxin type A is internalized and
translocated from small synaptic vesicles at the neuromuscular junction. Mol.
Neurobiol. 48, 120–127.
[23] Pirazzini, M., Rossetto, O., Bolognese, P., Shone, C.C. and Montecucco, C. (2011)
Double anchorage to the membrane and intact inter-chain disulﬁde bond are
required for the low pH induced entry of tetanus and botulinum neurotoxins
into neurons. Cell. Microbiol. 13, 1731–1743.
[24] Swaminathan, S. and Eswaramoorthy, S. (2000) Structural analysis of the
catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct.
Biol. 7, 693–699.
[25] Rummel, A., Mahrhold, S., Bigalke, H. and Binz, T. (2004) The HCC-domain of
botulinum neurotoxins A and B exhibits a singular ganglioside binding site
displaying serotype speciﬁc carbohydrate interaction. Mol. Microbiol. 51,
631–643.
[26] Rigoni, M. et al. (2004) Snake presynaptic neurotoxins with phospholipase A2
activity induce punctate swellings of neurites and exocytosis of synaptic
vesicles. J. Cell Sci. 117, 3561–3570.
[27] Olsson, M.H.M., Sondergaard, C.R., Rostkowski, M. and Jensen, J.H. (2011)
PROPKA3: consistent treatment of internal and surface residues in empirical
pK(a) predictions. J. Chem. Theory Comput. 7, 525–537.
[28] Sun, S., Suresh, S., Liu, H., Tepp, W.H., Johnson, E.A., Edwardson, J.M. and
Chapman, E.R. (2011) Receptor binding enables botulinum neurotoxin B to
sense low pH for translocation channel assembly. Cell Host Microbe 10, 237–
247.
[29] Pirazzini, M., Rossetto, O., Bertasio, C., Bordin, F., Shone, C.C., Binz, T. and
Montecucco, C. (2013) Time course and temperature dependence of the
membrane translocation of tetanus and botulinum neurotoxins C and D in
neurons. Biochem. Biophys. Res. Commun. 430, 38–42.
[30] Perier, A. et al. (2007) Concerted protonation of key histidines triggers
membrane interaction of the diphtheria toxin T domain. J. Biol. Chem. 282,
24239–24245.
[31] Rodnin, M.V., Kyrychenko, A., Kienker, P., Sharma, O., Posokhov, Y.O., Collier,
R.J., Finkelstein, A. and Ladokhin, A.S. (2010) Conformational switching of the
diphtheria toxin T domain. J. Mol. Biol. 402, 1–7.
[32] Jin, R., Rummel, A., Binz, T. and Brunger, A.T. (2006) Botulinum neurotoxin B
recognizes its protein receptor with high afﬁnity and speciﬁcity. Nature 444,
1092–1095.
[33] Eswaramoorthy, S., Kumaran, D., Keller, J. and Swaminathan, S. (2004) Role of
metals in the biological activity of Clostridium botulinum neurotoxins.
Biochemistry 43, 2209–2216.
3836 M. Pirazzini et al. / FEBS Letters 587 (2013) 3831–3836[34] Montal, M.S., Blewitt, R., Tomich, J.M. and Montal, M. (1992) Identiﬁcation of
an ion channel-forming motif in the primary structure of tetanus and
botulinum neurotoxins. FEBS Lett. 313, 12–18.
[35] Galloux, M., Vitrac, H., Montagner, C., Raffestin, S., Popoff, M.R., Chenal, A.,
Forge, V. and Gillet, D. (2008) Membrane Interaction of botulinum neurotoxin
A translocation (T) domain. The belt region is a regulatory loop for membrane
interaction. J. Biol. Chem. 283, 27668–27676.[36] Fischer, A. (2013) Synchronized chaperone function of botulinum neurotoxin
domains mediates light chain translocation into neurons. Curr. Top. Microbiol.
Immunol. 364, 115–137.
[37] Koriazova, L.K. and Montal, M. (2003) Translocation of botulinum neurotoxin
light chain protease through the heavy chain channel. Nat. Struct. Biol. 10, 13–
18.
